Galectin-1 prevents pathological vascular remodeling in atherosclerosis and abdominal aortic aneurysm

Autores
Roldán Montero, Raquel; Pérez Sáez, Juan Manuel; Cerro Pardo, Isabel; Oller, Jorge; Martinez Lopez, Diego; Nuñez, Estefania; Maller, Sebastian Matias; Gutierrez Muñoz, Carmen; Mendez Barbero, Nerea; Escola Gil, Joan C.; Michel, Jean Baptiste; Mittelbrunn, Maria; Vázquez, Jesús; Blanco Colio, Luis M.; Rabinovich, Gabriel Adrián; Martin Ventura, Jose L.
Año de publicación
2022
Idioma
inglés
Tipo de recurso
artículo
Estado
versión publicada
Descripción
Pathological vascular remodeling is the underlying cause of atherosclerosis and abdominal aortic aneurysm (AAA). Here, we analyzed the role of galectin-1 (Gal-1), a β-galactoside-binding protein, as a therapeutic target for atherosclerosis and AAA. Mice lacking Gal-1 (Lgals1-/-) developed severe atherosclerosis induced by pAAV/D377Y-mPCSK9 adenovirus and displayed higher lipid levels and lower expression of contractile markers of vascular smooth muscle cells (VSMCs) in plaques than wild-type mice. Proteomic analysis of Lgals1-/- aortas showed changes in markers of VSMC phenotypic switch and altered composition of mitochondrial proteins. Mechanistically, Gal-1 silencing resulted in increased foam cell formation and mitochondrial dysfunction in VSMCs, while treatment with recombinant Gal-1 (rGal-1) prevented these effects. Furthermore, rGal-1 treatment attenuated atherosclerosis and elastase-induced AAA, leading to higher contractile VSMCs in aortic tissues. Gal-1 expression decreased in human atheroma and AAA compared to control tissue. Thus, Gal-1-driven circuits emerge as potential therapeutic strategies in atherosclerosis and AAA.
Fil: Roldán Montero, Raquel. Universidad Autónoma de Madrid; España
Fil: Pérez Sáez, Juan Manuel. Consejo Nacional de Investigaciones Científicas y Técnicas. Instituto de Biología y Medicina Experimental. Fundación de Instituto de Biología y Medicina Experimental. Instituto de Biología y Medicina Experimental; Argentina
Fil: Cerro Pardo, Isabel. Universidad Autónoma de Madrid; España
Fil: Oller, Jorge. Consejo Superior de Investigaciones Científicas; España
Fil: Martinez Lopez, Diego. Universidad Autónoma de Madrid; España
Fil: Nuñez, Estefania. Instituto de Salud Carlos III; España
Fil: Maller, Sebastian Matias. Consejo Nacional de Investigaciones Científicas y Técnicas. Instituto de Biología y Medicina Experimental. Fundación de Instituto de Biología y Medicina Experimental. Instituto de Biología y Medicina Experimental; Argentina
Fil: Gutierrez Muñoz, Carmen. Universidad Autónoma de Madrid; España
Fil: Mendez Barbero, Nerea. Universidad Autónoma de Madrid; España
Fil: Escola Gil, Joan C.. Instituto de Salud Carlos III; España
Fil: Michel, Jean Baptiste. Inserm; Francia
Fil: Mittelbrunn, Maria. Universidad Autónoma de Madrid; España
Fil: Vázquez, Jesús. Instituto de Salud Carlos III; España
Fil: Blanco Colio, Luis M.. Universidad Autónoma de Madrid; España
Fil: Rabinovich, Gabriel Adrián. Consejo Nacional de Investigaciones Científicas y Técnicas. Instituto de Biología y Medicina Experimental. Fundación de Instituto de Biología y Medicina Experimental. Instituto de Biología y Medicina Experimental; Argentina. Universidad de Buenos Aires. Facultad de Ciencias Exactas y Naturales. Departamento de Química Biológica; Argentina
Fil: Martin Ventura, Jose L.. Universidad Autónoma de Madrid; España
Materia
ATHEROSCLEROSIS
GALECTIN-1
AORTIC ANEURYSM
MUSCLE, SMOOTH, VASCULAR
MICE
Nivel de accesibilidad
acceso abierto
Condiciones de uso
https://creativecommons.org/licenses/by-nc-sa/2.5/ar/
Repositorio
CONICET Digital (CONICET)
Institución
Consejo Nacional de Investigaciones Científicas y Técnicas
OAI Identificador
oai:ri.conicet.gov.ar:11336/203879
Acceder
id CONICETDig_d6ec4244eed82169a11b6474c837db20
oai_identifier_str oai:ri.conicet.gov.ar:11336/203879
network_acronym_str CONICETDig
repository_id_str 3498
network_name_str CONICET Digital (CONICET)
spelling Galectin-1 prevents pathological vascular remodeling in atherosclerosis and abdominal aortic aneurysmRoldán Montero, RaquelPérez Sáez, Juan ManuelCerro Pardo, IsabelOller, JorgeMartinez Lopez, DiegoNuñez, EstefaniaMaller, Sebastian MatiasGutierrez Muñoz, CarmenMendez Barbero, NereaEscola Gil, Joan C.Michel, Jean BaptisteMittelbrunn, MariaVázquez, JesúsBlanco Colio, Luis M.Rabinovich, Gabriel AdriánMartin Ventura, Jose L.ATHEROSCLEROSISGALECTIN-1AORTIC ANEURYSMMUSCLE, SMOOTH, VASCULARMICEhttps://purl.org/becyt/ford/3.1https://purl.org/becyt/ford/3Pathological vascular remodeling is the underlying cause of atherosclerosis and abdominal aortic aneurysm (AAA). Here, we analyzed the role of galectin-1 (Gal-1), a β-galactoside-binding protein, as a therapeutic target for atherosclerosis and AAA. Mice lacking Gal-1 (Lgals1-/-) developed severe atherosclerosis induced by pAAV/D377Y-mPCSK9 adenovirus and displayed higher lipid levels and lower expression of contractile markers of vascular smooth muscle cells (VSMCs) in plaques than wild-type mice. Proteomic analysis of Lgals1-/- aortas showed changes in markers of VSMC phenotypic switch and altered composition of mitochondrial proteins. Mechanistically, Gal-1 silencing resulted in increased foam cell formation and mitochondrial dysfunction in VSMCs, while treatment with recombinant Gal-1 (rGal-1) prevented these effects. Furthermore, rGal-1 treatment attenuated atherosclerosis and elastase-induced AAA, leading to higher contractile VSMCs in aortic tissues. Gal-1 expression decreased in human atheroma and AAA compared to control tissue. Thus, Gal-1-driven circuits emerge as potential therapeutic strategies in atherosclerosis and AAA.Fil: Roldán Montero, Raquel. Universidad Autónoma de Madrid; EspañaFil: Pérez Sáez, Juan Manuel. Consejo Nacional de Investigaciones Científicas y Técnicas. Instituto de Biología y Medicina Experimental. Fundación de Instituto de Biología y Medicina Experimental. Instituto de Biología y Medicina Experimental; ArgentinaFil: Cerro Pardo, Isabel. Universidad Autónoma de Madrid; EspañaFil: Oller, Jorge. Consejo Superior de Investigaciones Científicas; EspañaFil: Martinez Lopez, Diego. Universidad Autónoma de Madrid; EspañaFil: Nuñez, Estefania. Instituto de Salud Carlos III; EspañaFil: Maller, Sebastian Matias. Consejo Nacional de Investigaciones Científicas y Técnicas. Instituto de Biología y Medicina Experimental. Fundación de Instituto de Biología y Medicina Experimental. Instituto de Biología y Medicina Experimental; ArgentinaFil: Gutierrez Muñoz, Carmen. Universidad Autónoma de Madrid; EspañaFil: Mendez Barbero, Nerea. Universidad Autónoma de Madrid; EspañaFil: Escola Gil, Joan C.. Instituto de Salud Carlos III; EspañaFil: Michel, Jean Baptiste. Inserm; FranciaFil: Mittelbrunn, Maria. Universidad Autónoma de Madrid; EspañaFil: Vázquez, Jesús. Instituto de Salud Carlos III; EspañaFil: Blanco Colio, Luis M.. Universidad Autónoma de Madrid; EspañaFil: Rabinovich, Gabriel Adrián. Consejo Nacional de Investigaciones Científicas y Técnicas. Instituto de Biología y Medicina Experimental. Fundación de Instituto de Biología y Medicina Experimental. Instituto de Biología y Medicina Experimental; Argentina. Universidad de Buenos Aires. Facultad de Ciencias Exactas y Naturales. Departamento de Química Biológica; ArgentinaFil: Martin Ventura, Jose L.. Universidad Autónoma de Madrid; EspañaScience Advances is the American Association for the Advancement of Science2022-03info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionhttp://purl.org/coar/resource_type/c_6501info:ar-repo/semantics/articuloapplication/pdfapplication/pdfhttp://hdl.handle.net/11336/203879Roldán Montero, Raquel; Pérez Sáez, Juan Manuel; Cerro Pardo, Isabel; Oller, Jorge; Martinez Lopez, Diego; et al.; Galectin-1 prevents pathological vascular remodeling in atherosclerosis and abdominal aortic aneurysm; Science Advances is the American Association for the Advancement of Science; Science Advances; 8; 11; 3-2022; 1-142375-2548CONICET DigitalCONICETenginfo:eu-repo/semantics/altIdentifier/doi/10.1126/sciadv.abm7322info:eu-repo/semantics/openAccesshttps://creativecommons.org/licenses/by-nc-sa/2.5/ar/reponame:CONICET Digital (CONICET)instname:Consejo Nacional de Investigaciones Científicas y Técnicas2025-10-15T14:48:15Zoai:ri.conicet.gov.ar:11336/203879instacron:CONICETInstitucionalhttp://ri.conicet.gov.ar/Organismo científico-tecnológicoNo correspondehttp://ri.conicet.gov.ar/oai/requestdasensio@conicet.gov.ar; lcarlino@conicet.gov.arArgentinaNo correspondeNo correspondeNo correspondeopendoar:34982025-10-15 14:48:15.642CONICET Digital (CONICET) - Consejo Nacional de Investigaciones Científicas y Técnicasfalse
dc.title.none.fl_str_mv Galectin-1 prevents pathological vascular remodeling in atherosclerosis and abdominal aortic aneurysm
title Galectin-1 prevents pathological vascular remodeling in atherosclerosis and abdominal aortic aneurysm
spellingShingle Galectin-1 prevents pathological vascular remodeling in atherosclerosis and abdominal aortic aneurysm
Roldán Montero, Raquel
ATHEROSCLEROSIS
GALECTIN-1
AORTIC ANEURYSM
MUSCLE, SMOOTH, VASCULAR
MICE
title_short Galectin-1 prevents pathological vascular remodeling in atherosclerosis and abdominal aortic aneurysm
title_full Galectin-1 prevents pathological vascular remodeling in atherosclerosis and abdominal aortic aneurysm
title_fullStr Galectin-1 prevents pathological vascular remodeling in atherosclerosis and abdominal aortic aneurysm
title_full_unstemmed Galectin-1 prevents pathological vascular remodeling in atherosclerosis and abdominal aortic aneurysm
title_sort Galectin-1 prevents pathological vascular remodeling in atherosclerosis and abdominal aortic aneurysm
dc.creator.none.fl_str_mv Roldán Montero, Raquel
Pérez Sáez, Juan Manuel
Cerro Pardo, Isabel
Oller, Jorge
Martinez Lopez, Diego
Nuñez, Estefania
Maller, Sebastian Matias
Gutierrez Muñoz, Carmen
Mendez Barbero, Nerea
Escola Gil, Joan C.
Michel, Jean Baptiste
Mittelbrunn, Maria
Vázquez, Jesús
Blanco Colio, Luis M.
Rabinovich, Gabriel Adrián
Martin Ventura, Jose L.
author Roldán Montero, Raquel
author_facet Roldán Montero, Raquel
Pérez Sáez, Juan Manuel
Cerro Pardo, Isabel
Oller, Jorge
Martinez Lopez, Diego
Nuñez, Estefania
Maller, Sebastian Matias
Gutierrez Muñoz, Carmen
Mendez Barbero, Nerea
Escola Gil, Joan C.
Michel, Jean Baptiste
Mittelbrunn, Maria
Vázquez, Jesús
Blanco Colio, Luis M.
Rabinovich, Gabriel Adrián
Martin Ventura, Jose L.
author_role author
author2 Pérez Sáez, Juan Manuel
Cerro Pardo, Isabel
Oller, Jorge
Martinez Lopez, Diego
Nuñez, Estefania
Maller, Sebastian Matias
Gutierrez Muñoz, Carmen
Mendez Barbero, Nerea
Escola Gil, Joan C.
Michel, Jean Baptiste
Mittelbrunn, Maria
Vázquez, Jesús
Blanco Colio, Luis M.
Rabinovich, Gabriel Adrián
Martin Ventura, Jose L.
author2_role author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
dc.subject.none.fl_str_mv ATHEROSCLEROSIS
GALECTIN-1
AORTIC ANEURYSM
MUSCLE, SMOOTH, VASCULAR
MICE
topic ATHEROSCLEROSIS
GALECTIN-1
AORTIC ANEURYSM
MUSCLE, SMOOTH, VASCULAR
MICE
purl_subject.fl_str_mv https://purl.org/becyt/ford/3.1
https://purl.org/becyt/ford/3
dc.description.none.fl_txt_mv Pathological vascular remodeling is the underlying cause of atherosclerosis and abdominal aortic aneurysm (AAA). Here, we analyzed the role of galectin-1 (Gal-1), a β-galactoside-binding protein, as a therapeutic target for atherosclerosis and AAA. Mice lacking Gal-1 (Lgals1-/-) developed severe atherosclerosis induced by pAAV/D377Y-mPCSK9 adenovirus and displayed higher lipid levels and lower expression of contractile markers of vascular smooth muscle cells (VSMCs) in plaques than wild-type mice. Proteomic analysis of Lgals1-/- aortas showed changes in markers of VSMC phenotypic switch and altered composition of mitochondrial proteins. Mechanistically, Gal-1 silencing resulted in increased foam cell formation and mitochondrial dysfunction in VSMCs, while treatment with recombinant Gal-1 (rGal-1) prevented these effects. Furthermore, rGal-1 treatment attenuated atherosclerosis and elastase-induced AAA, leading to higher contractile VSMCs in aortic tissues. Gal-1 expression decreased in human atheroma and AAA compared to control tissue. Thus, Gal-1-driven circuits emerge as potential therapeutic strategies in atherosclerosis and AAA.
Fil: Roldán Montero, Raquel. Universidad Autónoma de Madrid; España
Fil: Pérez Sáez, Juan Manuel. Consejo Nacional de Investigaciones Científicas y Técnicas. Instituto de Biología y Medicina Experimental. Fundación de Instituto de Biología y Medicina Experimental. Instituto de Biología y Medicina Experimental; Argentina
Fil: Cerro Pardo, Isabel. Universidad Autónoma de Madrid; España
Fil: Oller, Jorge. Consejo Superior de Investigaciones Científicas; España
Fil: Martinez Lopez, Diego. Universidad Autónoma de Madrid; España
Fil: Nuñez, Estefania. Instituto de Salud Carlos III; España
Fil: Maller, Sebastian Matias. Consejo Nacional de Investigaciones Científicas y Técnicas. Instituto de Biología y Medicina Experimental. Fundación de Instituto de Biología y Medicina Experimental. Instituto de Biología y Medicina Experimental; Argentina
Fil: Gutierrez Muñoz, Carmen. Universidad Autónoma de Madrid; España
Fil: Mendez Barbero, Nerea. Universidad Autónoma de Madrid; España
Fil: Escola Gil, Joan C.. Instituto de Salud Carlos III; España
Fil: Michel, Jean Baptiste. Inserm; Francia
Fil: Mittelbrunn, Maria. Universidad Autónoma de Madrid; España
Fil: Vázquez, Jesús. Instituto de Salud Carlos III; España
Fil: Blanco Colio, Luis M.. Universidad Autónoma de Madrid; España
Fil: Rabinovich, Gabriel Adrián. Consejo Nacional de Investigaciones Científicas y Técnicas. Instituto de Biología y Medicina Experimental. Fundación de Instituto de Biología y Medicina Experimental. Instituto de Biología y Medicina Experimental; Argentina. Universidad de Buenos Aires. Facultad de Ciencias Exactas y Naturales. Departamento de Química Biológica; Argentina
Fil: Martin Ventura, Jose L.. Universidad Autónoma de Madrid; España
description Pathological vascular remodeling is the underlying cause of atherosclerosis and abdominal aortic aneurysm (AAA). Here, we analyzed the role of galectin-1 (Gal-1), a β-galactoside-binding protein, as a therapeutic target for atherosclerosis and AAA. Mice lacking Gal-1 (Lgals1-/-) developed severe atherosclerosis induced by pAAV/D377Y-mPCSK9 adenovirus and displayed higher lipid levels and lower expression of contractile markers of vascular smooth muscle cells (VSMCs) in plaques than wild-type mice. Proteomic analysis of Lgals1-/- aortas showed changes in markers of VSMC phenotypic switch and altered composition of mitochondrial proteins. Mechanistically, Gal-1 silencing resulted in increased foam cell formation and mitochondrial dysfunction in VSMCs, while treatment with recombinant Gal-1 (rGal-1) prevented these effects. Furthermore, rGal-1 treatment attenuated atherosclerosis and elastase-induced AAA, leading to higher contractile VSMCs in aortic tissues. Gal-1 expression decreased in human atheroma and AAA compared to control tissue. Thus, Gal-1-driven circuits emerge as potential therapeutic strategies in atherosclerosis and AAA.
publishDate 2022
dc.date.none.fl_str_mv 2022-03
dc.type.none.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
http://purl.org/coar/resource_type/c_6501
info:ar-repo/semantics/articulo
format article
status_str publishedVersion
dc.identifier.none.fl_str_mv http://hdl.handle.net/11336/203879
Roldán Montero, Raquel; Pérez Sáez, Juan Manuel; Cerro Pardo, Isabel; Oller, Jorge; Martinez Lopez, Diego; et al.; Galectin-1 prevents pathological vascular remodeling in atherosclerosis and abdominal aortic aneurysm; Science Advances is the American Association for the Advancement of Science; Science Advances; 8; 11; 3-2022; 1-14
2375-2548
CONICET Digital
CONICET
url http://hdl.handle.net/11336/203879
identifier_str_mv Roldán Montero, Raquel; Pérez Sáez, Juan Manuel; Cerro Pardo, Isabel; Oller, Jorge; Martinez Lopez, Diego; et al.; Galectin-1 prevents pathological vascular remodeling in atherosclerosis and abdominal aortic aneurysm; Science Advances is the American Association for the Advancement of Science; Science Advances; 8; 11; 3-2022; 1-14
2375-2548
CONICET Digital
CONICET
dc.language.none.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv info:eu-repo/semantics/altIdentifier/doi/10.1126/sciadv.abm7322
dc.rights.none.fl_str_mv info:eu-repo/semantics/openAccess
https://creativecommons.org/licenses/by-nc-sa/2.5/ar/
eu_rights_str_mv openAccess
rights_invalid_str_mv https://creativecommons.org/licenses/by-nc-sa/2.5/ar/
dc.format.none.fl_str_mv application/pdf
application/pdf
dc.publisher.none.fl_str_mv Science Advances is the American Association for the Advancement of Science
publisher.none.fl_str_mv Science Advances is the American Association for the Advancement of Science
dc.source.none.fl_str_mv reponame:CONICET Digital (CONICET)
instname:Consejo Nacional de Investigaciones Científicas y Técnicas
reponame_str CONICET Digital (CONICET)
collection CONICET Digital (CONICET)
instname_str Consejo Nacional de Investigaciones Científicas y Técnicas
repository.name.fl_str_mv CONICET Digital (CONICET) - Consejo Nacional de Investigaciones Científicas y Técnicas
repository.mail.fl_str_mv dasensio@conicet.gov.ar; lcarlino@conicet.gov.ar
_version_ 1846083002202849280
score 13.22299

Publicaciones similares